Clinical Trial: Application Research of Methylation Markers in Early-stage Lung Cancer Patients Treated With Co-ablation System Therapy

U.S., Dec. 3 -- ClinicalTrials.gov registry received information related to the study (NCT07257471) titled 'Application Research of Methylation Markers in Early-stage Lung Cancer Patients Treated With Co-ablation System Therapy' on Nov. 17.

Brief Summary: Lung cancer has the highest global incidence and mortality among malignancies. While surgery is the primary curative treatment for early-stage patients, approximately 25-35% are ineligible due to comorbidities. For these patients, Co-ablation system therapy is a key minimally invasive option. However, even after imaging indicates complete tumor removal ("tumor-free status"), minimal residual disease (MRD) may persist, leading to recurrence.

Current mainstream MRD detection relies on iden...